US61225M1027
US61225M1027
Monte Rosa Therapeutics, Inc.
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2025 | 2024 | Change % |
|---|---|---|---|
| Total Revenue | 123.672.000 | 75.622.000 | 63.5% |
| Cost of Revenue | -- | -- | -- |
| Gross Profit | -- | -- | -- |
| 177.880.000 | 156.734.000 | 13.5% | |
| Operating Income | -54.208.000 | -81.112.000 | 33.2% |
| Pretax Income | -39.723.000 | -70.130.000 | 43.4% |
| Net Income Common Stockholders | -38.626.000 | -72.700.000 | 46.9% |
| -- | -- | -- | |
| -- | -- | -- |